However, our subsequent study did not show any advantage for leflunomide plus IFN-α-2a beyond IFN-α-2a alone in terms of duration of viral shedding in COVID-19 patients with prolonged post-symptomatic viral shedding (12). The gene discussed is IFNA2; the disease is COVID-19.